CEND-1: a game changer for pancreatic cancer chemotherapy?

Affiliations

¹ Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany.
² Department of General Visceral and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany. Electronic address: john.neoptolemos@med.uni-heidelberg.de.

Comment

Christoph Springfeld et al. Lancet Gastroenterol Hepatol. 2022 Oct.

. 2022 Oct;7(10):900-902.

doi: 10.1016/S2468-1253(22)00197-2. Epub 2022 Jul 6.

¹ Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany.
² Department of General Visceral and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany. Electronic address: john.neoptolemos@med.uni-heidelberg.de.

No abstract available

Conflict of interest statement

CS has participated on advisory boards for AstraZeneca, Bayer, BMS, Eisai, MSD, and Roche. JPN declares no competing interests.

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study.
Dean A, Gill S, McGregor M, Broadbridge V, Järveläinen HA, Price T. Dean A, et al. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):943-951. doi: 10.1016/S2468-1253(22)00167-4. Epub 2022 Jul 6. Lancet Gastroenterol Hepatol. 2022. PMID: 35803294 Clinical Trial.